GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

finance.yahoo.com
·

GSK eyes up combo approval for previously withdrawn myeloma drug

GSK’s Blenrep, withdrawn in 2022, seeks FDA approval in combination with Velcade/dexamethasone or Pomalyst/dexamethasone for multiple myeloma patients with prior therapy. Based on DREAMM-7 and DREAMM-8 trials, Blenrep combos showed significant PFS improvements over standard-of-care, with manageable safety profiles. Expected to compete with BCMA CAR-T therapies like Carvykti and Tecvayli, Blenrep could offer simpler IV infusion benefits.
genengnews.com
·

Xiaorong He on Boehringer Ingelheim's Investments in AI, Broader Applications in Pharma

Xiaorong He, Boehringer Ingelheim's senior VP, discusses AI's role in pharma, highlighting investments in AI-based tech, partnerships with Ten63, Phenomic AI, Google Quantum AI, and IBM. AI applications span drug discovery to clinical trials, aiming to enhance success rates and streamline processes, with examples like ADAM and IQNow. Future AI in pharma is expected to boost productivity, speed, and resource utilization, with ongoing initiatives in sustainability and patient-centricity.

Oncopole: Québec's catalyst for cancer research and innovation

Oncopole unites partners to accelerate cancer research in Québec, focusing on treatment, prevention, and patient care. It supports basic, translational, and clinical research, aiming to position Québec as a leader in cancer research. The Innovative Cancer Engineering (ICE) facility and the Québec Cancer Research Network (RRCancer) drive innovation through collaborative efforts and advanced research infrastructure, emphasizing precision oncology and personalized treatments.
morningstar.co.uk
·

GSK's Blenrep combinations accepted for review by US FDA

GSK's Blenrep combinations for relapsed and refractory multiple myeloma accepted by the US FDA, with a decision expected by July 23. The application covers Blenrep with BorDex and PomDex for patients who have undergone at least one prior therapy.

FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory

GSK's BLA for Blenrep in combinations with bortezomib plus dexamethasone (BVd) and pomalidomide plus dexamethasone (BPd) for multiple myeloma treatment accepted by FDA, with action date of 23 July 2025. Based on DREAMM-7 and DREAMM-8 trials, showing significant PFS improvements.
gsk.com
·

Blenrep combinations accepted for review by the US FDA for the treatment of relapsed

GSK's Blenrep (belantamab mafodotin) combinations with BorDex (BVd) and PomDex (BPd) for multiple myeloma treatment, supported by DREAMM-7 and DREAMM-8 trials, submitted for FDA review with an action date of 23 July 2025. DREAMM-7 showed statistically significant overall survival benefits.

USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma

USFDA accepts Blenrep combinations for review in treating relapsed/refractory multiple myeloma, potentially transforming treatment options with manageable side effects.
gsk.com
·

Stock-exchange announcement

The article contains technical details about a PDF document structure, including metadata and viewer preferences.
openpr.com
·

Nasal Polyposis Clinical Trials 2024: EMA, PDMA, FDA Approvals

DelveInsight's 'Nasal Polyposis Pipeline Insight, 2024' report details the global development of 4+ Nasal Polyposis treatment therapies by 4+ key companies, including GlaxoSmithKline, Novartis, and AstraZeneca. Emerging therapies like Fasenra and Tezepelumab are expected to impact the market. The report covers clinical trials, mechanisms of action, route of administration, and market dynamics.
© Copyright 2024. All Rights Reserved by MedPath